The Relationship Between the Tumor Markers and Interstitial Lung Disease

the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients Clinical Trial

Official title:

The Relationship Between the Tumor Markers and Interstitial Lung Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04597814
• Other study ID #: yilunshen2020145
• Status: Completed
• Start date: January 1, 2019
• Est. completion date: October 15, 2020

Study information

• Verified date: October 2020
• Source: The First Affiliated Hospital of Guangzhou Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients. This study was undertaken to investigate the source of these serum tumor markers.

Description:

The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients. This study was undertaken to investigate the source of these serum tumor markers.We hypothesis that these tumor markers are released from the lung. The broncholveolr lvge fluid levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 were measured in the interstitial lung disease patients before lung transplantation. The immunohistochemical test was performed in the specimen lung after lung transplantation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: October 15, 2020
• Est. primary completion date: October 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria 1.Interstitial lung disease patients for lung transplantation -

Exclusion Criteria:

1. tumor

2. Interstitial lung disease patients could not be performed by lung transplantation

Related Conditions & MeSH terms

• Lung Diseases
• Lung Diseases, Interstitial
• the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients

Intervention

Other:
• No Intervention
No Intervention

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum levels of carcinoembryonic antigen (CEA)	serum levels of carcinoembryonic antigen (CEA)	6months
Primary	serum levels of carbohydrate antigen 19-9 (CA19-9)	serum levels of carbohydrate antigen 19-9 (CA19-9)	6months
Primary	serum levels of carbohydrate antigen 125(CA125)	serum levels of carbohydrate antigen 125(CA125)	6months
Primary	The alveolar lavage fluid levels of carcinoembryonic antigen (CEA)	The alveolar lavage fluid levels of carcinoembryonic antigen (CEA)	1 week
Primary	The alveolar lavage fluid levels of carbohydrate antigen 19-9 (CA19-9)	The alveolar lavage fluid levels of carbohydrate antigen 19-9 (CA19-9)	1 week
Primary	The alveolar lavage fluid levels of carbohydrate antigen 125	The alveolar lavage fluid levels of carbohydrate antigen 125	1 week
Primary	The lung tissue levels of carcinoembryonic antigen (CEA)	The lung tissue levels of carcinoembryonic antigen (CEA)	1 week
Primary	The lung tissue levels of carbohydrate antigen 19-9 (CA19-9)	The lung tissue levels of carbohydrate antigen 19-9 (CA19-9)	1 week
Primary	The lung tissue levels of carbohydrate antigen 125	The lung tissue levels of carbohydrate antigen 125	1 week